Prostatis Group LLC Merck & Co., Inc. Transaction History

Prostatis Group LLC

$343 Billion
Q4 2024

A detailed history of Prostatis Group LLC transactions in Merck & Co., Inc. stock. As of the latest transaction made, Prostatis Group LLC holds 2,773 shares of MRK stock, worth $248,904. This represents 0.08% of its overall portfolio holdings.

Number of Shares

2,773

Previous 3,466 19.99%

Holding current value

$248,904

Previous $394 Million 29.91%

% of portfolio

0.08%

Previous 0.13%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Mar 21, 2025	SELL	$96.31 - $114.76 $66,742 - $79,528	-693 Reduced 19.99%	2,773 $276 Million
Q3 2024 Mar 21, 2025	SELL	$111.15 - $128.97 $11,670 - $13,541	-105 Reduced 2.94%	3,466 $394 Million
Q2 2024 Mar 21, 2025	BUY	$123.8 - $132.96 $83,812 - $90,013	677 Added 23.39%	3,571 $442 Million
Q1 2024 Mar 21, 2025	SELL	$113.24 - $131.95 $18,911 - $22,035	-167 Reduced 5.46%	2,894 $382 Million
Q4 2023 Mar 21, 2025	SELL	$100.18 - $109.02 $29,653 - $32,269	-296 Reduced 8.82%	3,061 $334 Million
Q3 2023 Mar 21, 2025	SELL	$102.95 - $114.33 $17.8 Million - $19.7 Million	-172,568 Reduced 98.09%	3,357 $376 Million
Q2 2023 Aug 14, 2023	BUY	$108.61 - $118.38 $18.2 Million - $19.9 Million	167,711 Added 2041.77%	175,925 $349 Million
Q1 2023 May 22, 2023	SELL	$102.94 - $114.86 $3,191 - $3,560	-31 Reduced 0.38%	8,214 $891 Million
Q4 2022 Mar 28, 2023	BUY	$87.44 - $112.11 $503,479 - $645,529	5,758 Added 231.52%	8,245 $915 Million
Q4 2022 Mar 23, 2023	BUY	$87.44 - $112.11 $56.4 Million - $72.4 Million	645,400 Added 663.23%	742,711 $915 Million
Q3 2022 Mar 28, 2023	BUY	$84.53 - $94.96 $10,566 - $11,870	125 Added 5.29%	2,487 $214 Million
Q3 2022 Mar 23, 2023	SELL	$84.53 - $94.96 $464,915 - $522,279	-5,500 Reduced 5.35%	97,311 $214 Million
Q2 2022 Mar 28, 2023	SELL	$83.49 - $94.64 $166,896 - $189,185	-1,999 Reduced 45.84%	2,362 $215 Million
Q2 2022 Mar 23, 2023	BUY	$83.49 - $94.64 $892,007 - $1.01 Million	10,684 Added 11.6%	102,811 $215 Million
Q1 2022 Mar 23, 2023	BUY	$73.51 - $82.4 $482,372 - $540,708	6,562 Added 7.67%	92,127 $151 Million
Q4 2021 Mar 23, 2023	BUY	$72.28 - $90.54 $123,237 - $154,370	1,705 Added 2.03%	85,565 $99.8 Million
Q3 2021 Mar 23, 2023	SELL	$71.68 - $78.83 $212,387 - $233,573	-2,963 Reduced 3.41%	83,860 $97.7 Million
Q2 2021 Mar 23, 2023	BUY	$70.31 - $77.77 $48,935 - $54,127	696 Added 0.81%	86,823 $101 Million
Q1 2021 Mar 23, 2023	SELL	$68.86 - $81.11 $421,216 - $496,149	-6,117 Reduced 6.63%	86,127 $105 Million
Q4 2020 Mar 23, 2023	SELL	$71.77 - $79.65 $100,262 - $111,271	-1,397 Reduced 1.49%	92,244 $183 Million
Q3 2020 Mar 23, 2023	SELL	$73.18 - $82.95 $13.5 Million - $15.4 Million	-185,152 Reduced 66.41%	93,641 $195 Million
Q2 2020 Mar 28, 2023	SELL	$70.42 - $80.13 $52 Million - $59.2 Million	-738,350 Reduced 99.41%	4,361 $337 Million
Q2 2020 Mar 23, 2023	BUY	$70.42 - $80.13 $12.9 Million - $14.7 Million	183,662 Added 193.06%	278,793 $337 Million
Q1 2020 Mar 23, 2023	SELL	$63.36 - $87.82 $403,856 - $559,764	-6,374 Reduced 6.28%	95,131 $109 Million
Q4 2019 Mar 23, 2023	BUY	$77.58 - $87.54 $7.87 Million - $8.89 Million	101,505 New	101,505 $118 Million

Others Institutions Holding MRK

# of Institutions

3,954

Shares Held

1.86B

Call Options Held

16M

Put Options Held

15M

View Full List

About Merck & Co., Inc.

Ticker MRK
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,533,280,000
Market Cap $227B
Description
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, ...

More about MRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prostatis Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prostatis Group LLC with notifications on news.

Account

Prostatis Group LLC Merck & Co., Inc. Transaction History